These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8244259)

  • 1. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation.
    Manabe N; Chevallier M; Chossegros P; Causse X; Guerret S; Trépo C; Grimaud JA
    Hepatology; 1993 Dec; 18(6):1344-9. PubMed ID: 8244259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection.
    Tsubota A; Kumada H; Chayama K; Arase Y; Saitoh S; Koida I; Suzuki Y; Kobayashi M; Murashima N; Ikeda K
    J Hepatol; 1997 Jul; 27(1):49-55. PubMed ID: 9252073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
    Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
    Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
    Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
    Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.
    Ziol M; Nhieu JT; Roudot-Thoraval F; Métreau JM; Deugnier Y; Dhumeaux D; Zafrani ES
    J Hepatol; 1996 Dec; 25(6):833-41. PubMed ID: 9007710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.
    Causse X; Godinot H; Chevallier M; Chossegros P; Zoulim F; Ouzan D; Heyraud JP; Fontanges T; Albrecht J; Meschievitz C
    Gastroenterology; 1991 Aug; 101(2):497-502. PubMed ID: 1906028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.
    Hiramatsu N; Hayashi N; Kasahara A; Hagiwara H; Takehara T; Haruna Y; Naito M; Fusamoto H; Kamada T
    J Hepatol; 1995 Feb; 22(2):135-42. PubMed ID: 7790701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.
    Yamada M; Fukuda Y; Koyama Y; Nakano I; Urano F; Katano Y; Hayakawa T
    J Gastroenterol Hepatol; 1996 Jul; 11(7):646-51. PubMed ID: 8840240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy.
    Guéchot J; Loria A; Serfaty L; Giral P; Giboudeau J; Poupon R
    J Hepatol; 1995 Jan; 22(1):22-6. PubMed ID: 7751583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of active chronic hepatitis with recombinant alpha 2b-interferon: an 18 month follow-up.
    Bresci G; Parisi G; Banti S; Bertoni M
    Eur J Med; 1993; 2(6):349-52. PubMed ID: 8252180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histological evaluation of the liver and response to interferon in chronic hepatitis C].
    Yoshida H; Iwabuchi S; Murayama M; Uchikoshi T
    Nihon Rinsho; 1994 Jul; 52(7):1763-8. PubMed ID: 8078200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon.
    de Alava E; Camps J; Pardo-Mindán J; García-Granero M; Muñoz M; Sola J; Civeira MP; Contreras F; Vázquez JJ; Castilla A
    Liver; 1993 Apr; 13(2):73-9. PubMed ID: 8510490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C.
    Banner BF; Barton AL; Cable EE; Smith L; Bonkovsky HL
    Mod Pathol; 1995 Apr; 8(3):232-8. PubMed ID: 7542385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver.
    Reichen J; Bianchi L; Bühler H; Dolivo N; Gonvers JJ; Lavanchy D; Malé PJ; Renner EL; Solioz M; Schmid M; Zimmermann A
    J Hepatol; 1996 Sep; 25(3):275-82. PubMed ID: 8895005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection.
    Tsubota A; Chayama K; Ikeda K; Yasuji A; Koida I; Saitoh S; Hashimoto M; Iwasaki S; Kobayashi M; Hiromitsu K
    Hepatology; 1994 May; 19(5):1088-94. PubMed ID: 8175130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine.
    Kuloglu Z; Krsaçloglu CT; Kansu A; Erden E; Girgin N
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):564-8. PubMed ID: 18030234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.
    Schvarcz R; Glaumann H; Weiland O; Norkrans G; Wejstål R; Frydén A
    Liver; 1991 Feb; 11(1):30-8. PubMed ID: 1646369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial.
    David E; Pucci A; Palladin D; Saracco G; Garello E; Pintus C; Rocca G; Chiandussi L; Solinas A; Mollo F
    Am J Clin Pathol; 1992 Oct; 98(4):397-401. PubMed ID: 1415021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha-Interferon retreatment of patients with chronic hepatitis C.
    Rabinovitz M; Block G; Finkelstein SD
    Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.